Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: What does the future hold?

Drugs

Volumn 74, Issue 17, 2014, Pages 1983-1992

  Matera, Maria Gabriella ^a   Rogliani, Paola ^b   Calzetta, Luigino ^c   Cazzola, Mario ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PHOSPHODIESTERASE INHIBITORS;

AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; HUMAN; PHARMACOPHORE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84922079549     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0303-8     Document Type: Article

References (83)

1. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;204:391-414.
2. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs. 2003;63:2575-94.
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004;59:574-8.
4. Giembycz MA, Newton R. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Clin Chest Med. 2014;35:203-17.
5. European Medicines Agency. Daxas - Roflumilast. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/001179/WC500089626.pdf. Last accessed 28 May 2014.
6. FDA. US Food and Drug Administration FDA approves new drug to treat chronic obstructive pulmonary disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm. Last accessed 28 May 2014.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2014. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org/Guidelines/guidelines-resources.html. Last accessed 9 June 2014.
8. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;11:CD002309.
9. Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27:83-9.
10. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest. 2013;143:1302-11.
11. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
12. Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108:366-75.
13. O'Donnell DE, Bredenbröker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39:1104-12.
14. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180-4.
15. Pan L, Guo YZ, Zhang B, Yan JH. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis. 2013;5:422-9.
16. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.
17. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Eng J Med. 2010;363:1128-38.
18. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-20.
19. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004.
20. Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011;8:356-62.
21. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62:1081-7.
22. Milara J, Lluch J, Cano P, et al. Anti-inflammatory effects of dexamethasone, roflumilast N-oxide, formoterol and their combinations in human neutrophils from healthy and chronic obstructive pulmonary disease patients [abstract]. Am J Respir Crit Care Med. 2014;189:A2746.
23. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533:2-14.
24. Reddy AT, Lakshmi SP, Reddy RC. Roflumilast-glucocorticoid synergy in COPD [abstract]. Am J Respir Crit Care Med. 2014;189:A6666.
25. Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314-22.
26. Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol. 2011;204:415-46.
27. Grundy S, Plumb J, Kaur M, et al. Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells [abstract]. Eur Respir J. 2014;44(suppl):P1515.
28. Muñoz-Esquerre M, Diez-Ferrer M, Montón C, et al. Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: efficacy and tolerability [abstract]. Eur Respir J. 2014;44(suppl):P560.
29. De Backer J, Vos W, Van Holsbeke C, et al. A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers [abstract]. Eur Respir J. 2014;44(suppl):4670.
30. Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014;15:85-96.
31. Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008;155:308-15.
32. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275-86.
33. Bickston SJ, Snider KR, Kappus MR. Tetomilast: new promise for phosphodiesterase-4 inhibitors? Expert Opin Investig Drugs. 2012;21:1845-9.
34. ClinicalTrials.gov. Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (EMPHASIS). http://clinicaltrials.gov/ct2/show/study/NCT00874497?term=tetomilast&rank=3. Last accessed 27 June 2014.
35. ClinicalTrials.gov. To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients. http://clinicaltrials.gov/ct2/show/NCT00917150?term=tetomilast&rank=2. Last accessed 27 June 2014.
36. Gutke HJ, Guse JH, Khobzaoui M, et al. AWD-12-281 (inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs. 2005;6:1149-58.
37. Danto S, Wei GC, Gill J. A randomized, double-blind, placebo-controlled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD [abstract]. Am J Respir Crit Care Med. 2007;175:A131.
38. Vestbo J, Tan L, Atkinson G, Ward J. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J. 2009;33:1039-44.
39. Kobayashi M, Kubo S, Iwata M, et al. Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor. Int Immunopharmacol. 2011;11:732-9.
40. Chapman RW, House A, Richard J, et al. Pharmacology of SCH900182, a potent, selective inhibitor of PDE4 for inhaled administration [abstract]. Am J Respir Crit Care Med. 2010;181:A5671.
41. Kwak HJ, Nam JY, Song JS, et al. Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin induced asthma murine model. Eur J Pharmacol. 2012;685:141-8.
42. Yougbare I, Morin C, Senouvo FY, et al. NCS 613, a potent and specific PDE4 inhibitor, displays antiinflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol. 2011;301:L441-50.
43. Nials AT, Tralau-Stewart CJ, Gascoigne MH, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2011;337:137-44.
44. GlaxoSmithKline. Product development pipeline 2013. February 2013. http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK%202013%20Pipeline.pdf. Last accessed 14 March 2014.
45. Armani E, Amari G, Rizzi A, et al. A novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem. 2014;57:793-816.
46. ClinicalTrials.gov. Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients. http://clinicaltrials.gov/ct2/show/NCT01730404?term=PDE+COPD&recr=Open&rank=4. Last accessed 27 June 2014.
47. Moretto N, Caruso P, Marchini G, et al. CHF6001 is a novel highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with a robust in vitro anti-inflammatory profile [abstract]. Am J Respir Crit Care Med. 2014;189:A6725.
48. Marquez-Martin E, Ortega Ruiz F, Campano E, et al. Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD [abstract]. Eur Respir J 2014;44 (suppl):P926.
49. Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290-314.
50. Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J. 2014;44:475-82.
51. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase inhibitors just more theophylline? J Allergy Clin Immunol. 2006;117:1237-43.
52. Chung FK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006;533:110-7.
53. Foster RW, Rakshi K, Carpenter JR, Small RC. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol. 1992;34:527-34.
54. Ochiai K, Takita S, Kojima A, et al. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013;23:375-81.
55. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4Hpyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther. 2006;318:840-8.
56. Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346:414-23.
57. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL 554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1:714-27.
58. Wedzicha JA. Dual PDE3/4 inhibition: a novel approach to airway disease? Lancet Respir Med. 2013;1:669-70.
59. Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol. 2014;114:365-76.
60. Jones NA, Leport M, Holand T, et al. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm Pharmacol Ther. 2007;20:60-8.
61. Safavi M, Baeeri M, Abdollahi M. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Drug Discov. 2013;8:733-51.
62. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+T-lymphocytes. Mol Pharmacol. 2004;66:1679-89.
63. Fortin M, D'Anjou H, Higgins ME, et al. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir Res. 2009;10:39.
64. Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16:89-107.
65. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2009;18:1505-17.
66. Charan NB. Does sildenafil also improve breathing? Chest. 2001;120:305-6.
67. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med. 2004;169:227-34.
68. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol. 2005;5:238-44.
69. Rocco PR, Momesso DP, Figueira RC, et al. Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury. Eur Respir J. 2003;22:20-7.
70. Guimaraes IH, Padilha GDA, Lopes-Pacheco M, et al. Therapy with a new phosphodiesterase 4 and 5 inhibitor in experimental elastase-induced emphysema [abstract]. Am J Respir Crit Care Med. 2014;189:A6557.
71. Campos HS, Xisto DG, Oliveira MB, et al. Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma. Braz J Med Biol Res. 2006;39:283-7.
72. Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013;42:982-92.
73. Chan S, Yan C. PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol. 2011;11:720-4.
74. Kita T, Fujimura M, Myou S, et al. Effects of KF19514, a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma. Allergol Int. 2009;58:267-75.
75. Tannheimer SL, Sorensen EA, Cui Z-H, et al. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist. J Pharmacol Exp Ther. 2014;349:85-93.
76. Liu A, Huang L, Wang Z, et al. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. Bioorg Med Chem Lett. 2013;23:1548-52.
77. Huang L, Shan W, Zhou Q, et al. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. Bioorg Med Chem Lett. 2014;24:249-53.
78. Phillips G, Salmon M. Bifunctional compounds for the treatment of COPD. Ann Rep Med Chem. 2012;47:209-22.
79. Provins L, Christophe B, Danhaive P, et al. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006;16:1834-9.
80. Provins L, Christophe B, Danhaive P, et al. Dual M3 antagonists-PDE4 inhibitors. Part 2: synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett. 2007;17:3077-80.
81. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165:1288-305.
82. Lomas O, Zaccolo M. Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides. Physiology (Bethesda). 2014;29:141-9.
83. Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS. AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol. 2012;52:351-8.